“Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Body Surface Area (BSA) Involvement and Baseline Psoriasis Area and Severity Index (PASI)”. SKIN The Journal of Cutaneous Medicine 7, no. 2 (March 13, 2023): s120. Accessed April 3, 2025. https://skin.dermsquared.com/skin/article/view/1959.